NO148924B - ANALOGY PROCEDURE FOR THE PREPARATION OF IMMUNPOTENTPENSING PEPTIDES - Google Patents
ANALOGY PROCEDURE FOR THE PREPARATION OF IMMUNPOTENTPENSING PEPTIDES Download PDFInfo
- Publication number
- NO148924B NO148924B NO821608A NO821608A NO148924B NO 148924 B NO148924 B NO 148924B NO 821608 A NO821608 A NO 821608A NO 821608 A NO821608 A NO 821608A NO 148924 B NO148924 B NO 148924B
- Authority
- NO
- Norway
- Prior art keywords
- obzl
- glu
- lys
- boc
- val
- Prior art date
Links
- 108090000765 processed proteins & peptides Proteins 0.000 title claims description 12
- 102000004196 processed proteins & peptides Human genes 0.000 title claims description 7
- 238000000034 method Methods 0.000 title claims description 6
- 238000002360 preparation method Methods 0.000 title description 3
- UYWQUFXKFGHYNT-UHFFFAOYSA-N phenylmethyl ester of formic acid Natural products O=COCC1=CC=CC=C1 UYWQUFXKFGHYNT-UHFFFAOYSA-N 0.000 claims description 54
- 125000001584 benzyloxycarbonyl group Chemical group C(=O)(OCC1=CC=CC=C1)* 0.000 claims description 53
- 150000003839 salts Chemical class 0.000 claims description 13
- 125000006239 protecting group Chemical group 0.000 claims description 7
- 150000001875 compounds Chemical class 0.000 claims description 6
- 125000001797 benzyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])* 0.000 claims description 3
- 229910052739 hydrogen Inorganic materials 0.000 claims description 3
- 230000002434 immunopotentiative effect Effects 0.000 claims description 3
- 239000001257 hydrogen Substances 0.000 claims description 2
- 125000004435 hydrogen atom Chemical class [H]* 0.000 claims description 2
- 238000004519 manufacturing process Methods 0.000 claims description 2
- 125000005931 tert-butyloxycarbonyl group Chemical group [H]C([H])([H])C(OC(*)=O)(C([H])([H])[H])C([H])([H])[H] 0.000 claims description 2
- ZMXDDKWLCZADIW-UHFFFAOYSA-N N,N-Dimethylformamide Chemical compound CN(C)C=O ZMXDDKWLCZADIW-UHFFFAOYSA-N 0.000 description 96
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 78
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 42
- XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 description 38
- WYURNTSHIVDZCO-UHFFFAOYSA-N Tetrahydrofuran Chemical compound C1CCOC1 WYURNTSHIVDZCO-UHFFFAOYSA-N 0.000 description 38
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Chemical compound O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 25
- SJRJJKPEHAURKC-UHFFFAOYSA-N N-Methylmorpholine Chemical compound CN1CCOCC1 SJRJJKPEHAURKC-UHFFFAOYSA-N 0.000 description 21
- 239000000047 product Substances 0.000 description 19
- YLQBMQCUIZJEEH-UHFFFAOYSA-N tetrahydrofuran Natural products C=1C=COC=1 YLQBMQCUIZJEEH-UHFFFAOYSA-N 0.000 description 19
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 18
- 239000007787 solid Substances 0.000 description 18
- 235000019439 ethyl acetate Nutrition 0.000 description 14
- 239000002253 acid Substances 0.000 description 13
- 229910004373 HOAc Inorganic materials 0.000 description 12
- NQTADLQHYWFPDB-UHFFFAOYSA-N N-Hydroxysuccinimide Chemical compound ON1C(=O)CCC1=O NQTADLQHYWFPDB-UHFFFAOYSA-N 0.000 description 12
- DTQVDTLACAAQTR-UHFFFAOYSA-N Trifluoroacetic acid Chemical compound OC(=O)C(F)(F)F DTQVDTLACAAQTR-UHFFFAOYSA-N 0.000 description 12
- PAFZNILMFXTMIY-UHFFFAOYSA-N cyclohexylamine Chemical compound NC1CCCCC1 PAFZNILMFXTMIY-UHFFFAOYSA-N 0.000 description 12
- QOSSAOTZNIDXMA-UHFFFAOYSA-N Dicylcohexylcarbodiimide Chemical compound C1CCCCC1N=C=NC1CCCCC1 QOSSAOTZNIDXMA-UHFFFAOYSA-N 0.000 description 11
- 239000000203 mixture Substances 0.000 description 11
- 239000003921 oil Substances 0.000 description 11
- 239000000706 filtrate Substances 0.000 description 10
- 239000011734 sodium Substances 0.000 description 10
- 239000003208 petroleum Substances 0.000 description 8
- XBPCUCUWBYBCDP-UHFFFAOYSA-N Dicyclohexylamine Chemical compound C1CCCCC1NC1CCCCC1 XBPCUCUWBYBCDP-UHFFFAOYSA-N 0.000 description 7
- 238000001704 evaporation Methods 0.000 description 7
- 230000008020 evaporation Effects 0.000 description 7
- 238000004809 thin layer chromatography Methods 0.000 description 7
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 6
- 238000006243 chemical reaction Methods 0.000 description 6
- 239000012043 crude product Substances 0.000 description 6
- 150000002148 esters Chemical class 0.000 description 6
- 239000000463 material Substances 0.000 description 6
- 239000002904 solvent Substances 0.000 description 6
- 238000003786 synthesis reaction Methods 0.000 description 6
- KRHYYFGTRYWZRS-UHFFFAOYSA-N Fluorane Chemical compound F KRHYYFGTRYWZRS-UHFFFAOYSA-N 0.000 description 5
- WHUUTDBJXJRKMK-VKHMYHEASA-N L-glutamic acid Chemical compound OC(=O)[C@@H](N)CCC(O)=O WHUUTDBJXJRKMK-VKHMYHEASA-N 0.000 description 5
- 239000012044 organic layer Substances 0.000 description 5
- 239000000243 solution Substances 0.000 description 5
- BGGHCRNCRWQABU-JTQLQIEISA-N (2s)-2-amino-5-oxo-5-phenylmethoxypentanoic acid Chemical compound OC(=O)[C@@H](N)CCC(=O)OCC1=CC=CC=C1 BGGHCRNCRWQABU-JTQLQIEISA-N 0.000 description 4
- CKGCFBNYQJDIGS-LBPRGKRZSA-N (2s)-2-azaniumyl-6-(phenylmethoxycarbonylamino)hexanoate Chemical compound [O-]C(=O)[C@@H]([NH3+])CCCCNC(=O)OCC1=CC=CC=C1 CKGCFBNYQJDIGS-LBPRGKRZSA-N 0.000 description 4
- KFZMGEQAYNKOFK-UHFFFAOYSA-N Isopropanol Chemical compound CC(C)O KFZMGEQAYNKOFK-UHFFFAOYSA-N 0.000 description 4
- RDOXTESZEPMUJZ-UHFFFAOYSA-N anisole Chemical compound COC1=CC=CC=C1 RDOXTESZEPMUJZ-UHFFFAOYSA-N 0.000 description 4
- 230000015572 biosynthetic process Effects 0.000 description 4
- 239000006227 byproduct Substances 0.000 description 4
- 239000012634 fragment Substances 0.000 description 4
- 238000005342 ion exchange Methods 0.000 description 4
- 239000000843 powder Substances 0.000 description 4
- 239000011541 reaction mixture Substances 0.000 description 4
- IBABAURSJXMCQJ-QWRGUYRKSA-N (2s)-3-methyl-2-[[(2s)-3-methyl-2-[(2-methylpropan-2-yl)oxycarbonylamino]butanoyl]amino]butanoic acid Chemical compound CC(C)[C@@H](C(O)=O)NC(=O)[C@H](C(C)C)NC(=O)OC(C)(C)C IBABAURSJXMCQJ-QWRGUYRKSA-N 0.000 description 3
- SLRMQYXOBQWXCR-UHFFFAOYSA-N 2154-56-5 Chemical compound [CH2]C1=CC=CC=C1 SLRMQYXOBQWXCR-UHFFFAOYSA-N 0.000 description 3
- ZMANZCXQSJIPKH-UHFFFAOYSA-N Triethylamine Chemical compound CCN(CC)CC ZMANZCXQSJIPKH-UHFFFAOYSA-N 0.000 description 3
- 239000013058 crude material Substances 0.000 description 3
- 238000001962 electrophoresis Methods 0.000 description 3
- VFRSADQPWYCXDG-LEUCUCNGSA-N ethyl (2s,5s)-5-methylpyrrolidine-2-carboxylate;2,2,2-trifluoroacetic acid Chemical compound OC(=O)C(F)(F)F.CCOC(=O)[C@@H]1CC[C@H](C)N1 VFRSADQPWYCXDG-LEUCUCNGSA-N 0.000 description 3
- 238000011065 in-situ storage Methods 0.000 description 3
- 239000002198 insoluble material Substances 0.000 description 3
- YWLICOCXPNQJPC-KRWDZBQOSA-N (2,5-dioxopyrrolidin-1-yl) (2s)-2-[(2-methylpropan-2-yl)oxycarbonylamino]-6-(phenylmethoxycarbonylamino)hexanoate Chemical compound C([C@H](NC(=O)OC(C)(C)C)C(=O)ON1C(CCC1=O)=O)CCCNC(=O)OCC1=CC=CC=C1 YWLICOCXPNQJPC-KRWDZBQOSA-N 0.000 description 2
- COMUWNFVTWKSDT-ZETCQYMHSA-N (2,5-dioxopyrrolidin-1-yl) (2s)-2-[(2-methylpropan-2-yl)oxycarbonylamino]propanoate Chemical compound CC(C)(C)OC(=O)N[C@@H](C)C(=O)ON1C(=O)CCC1=O COMUWNFVTWKSDT-ZETCQYMHSA-N 0.000 description 2
- POBDBYGSGKMZPH-NSHDSACASA-N (2,5-dioxopyrrolidin-1-yl) (2s)-3-methyl-2-[(2-methylpropan-2-yl)oxycarbonylamino]butanoate Chemical compound CC(C)(C)OC(=O)N[C@@H](C(C)C)C(=O)ON1C(=O)CCC1=O POBDBYGSGKMZPH-NSHDSACASA-N 0.000 description 2
- WXRGJQZMGGGTSS-JTQLQIEISA-N (2,5-dioxopyrrolidin-1-yl) (2s)-4-methyl-2-[(2-methylpropan-2-yl)oxycarbonylamino]pentanoate Chemical compound CC(C)(C)OC(=O)N[C@@H](CC(C)C)C(=O)ON1C(=O)CCC1=O WXRGJQZMGGGTSS-JTQLQIEISA-N 0.000 description 2
- KEULITJLZYZYPU-AWEZNQCLSA-N 4-o-benzyl 1-o-(2,5-dioxopyrrolidin-1-yl) (2s)-2-[(2-methylpropan-2-yl)oxycarbonylamino]butanedioate Chemical compound C([C@H](NC(=O)OC(C)(C)C)C(=O)ON1C(CCC1=O)=O)C(=O)OCC1=CC=CC=C1 KEULITJLZYZYPU-AWEZNQCLSA-N 0.000 description 2
- USFZMSVCRYTOJT-UHFFFAOYSA-N Ammonium acetate Chemical compound N.CC(O)=O USFZMSVCRYTOJT-UHFFFAOYSA-N 0.000 description 2
- CIWBSHSKHKDKBQ-JLAZNSOCSA-N Ascorbic acid Chemical compound OC[C@H](O)[C@H]1OC(=O)C(O)=C1O CIWBSHSKHKDKBQ-JLAZNSOCSA-N 0.000 description 2
- KDXKERNSBIXSRK-YFKPBYRVSA-N L-lysine Chemical compound NCCCC[C@H](N)C(O)=O KDXKERNSBIXSRK-YFKPBYRVSA-N 0.000 description 2
- KZSNJWFQEVHDMF-BYPYZUCNSA-N L-valine Chemical compound CC(C)[C@H](N)C(O)=O KZSNJWFQEVHDMF-BYPYZUCNSA-N 0.000 description 2
- FYYSQDHBALBGHX-YFKPBYRVSA-N N(alpha)-t-butoxycarbonyl-L-asparagine Chemical compound CC(C)(C)OC(=O)N[C@H](C(O)=O)CC(N)=O FYYSQDHBALBGHX-YFKPBYRVSA-N 0.000 description 2
- 108010046075 Thymosin Proteins 0.000 description 2
- 102000007501 Thymosin Human genes 0.000 description 2
- 206010053613 Type IV hypersensitivity reaction Diseases 0.000 description 2
- AGEZXYOZHKGVCM-UHFFFAOYSA-N benzyl bromide Chemical class BrCC1=CC=CC=C1 AGEZXYOZHKGVCM-UHFFFAOYSA-N 0.000 description 2
- NDKBVBUGCNGSJJ-UHFFFAOYSA-M benzyltrimethylammonium hydroxide Chemical compound [OH-].C[N+](C)(C)CC1=CC=CC=C1 NDKBVBUGCNGSJJ-UHFFFAOYSA-M 0.000 description 2
- 239000003795 chemical substances by application Substances 0.000 description 2
- 238000004440 column chromatography Methods 0.000 description 2
- 238000009833 condensation Methods 0.000 description 2
- 230000005494 condensation Effects 0.000 description 2
- 230000000694 effects Effects 0.000 description 2
- 238000001914 filtration Methods 0.000 description 2
- 239000010410 layer Substances 0.000 description 2
- UZKWTJUDCOPSNM-UHFFFAOYSA-N methoxybenzene Substances CCCCOC=C UZKWTJUDCOPSNM-UHFFFAOYSA-N 0.000 description 2
- 239000004570 mortar (masonry) Substances 0.000 description 2
- 239000002244 precipitate Substances 0.000 description 2
- 238000001953 recrystallisation Methods 0.000 description 2
- 238000003756 stirring Methods 0.000 description 2
- 239000006188 syrup Substances 0.000 description 2
- 235000020357 syrup Nutrition 0.000 description 2
- LCJVIYPJPCBWKS-NXPQJCNCSA-N thymosin Chemical compound SC[C@@H](N)C(=O)N[C@H](CO)C(=O)N[C@H](CC(O)=O)C(=O)N[C@@H](C)C(=O)N[C@@H](C)C(=O)N[C@H](C(C)C)C(=O)N[C@H](CC(O)=O)C(=O)N[C@H](C(C)C)C(=O)N[C@H](CO)C(=O)N[C@H](CO)C(=O)N[C@H](CCC(O)=O)C(=O)N[C@H]([C@@H](C)CC)C(=O)N[C@H]([C@H](C)O)C(=O)N[C@H](C(C)C)C(=O)N[C@H](CCCCN)C(=O)N[C@H](CC(O)=O)C(=O)N[C@H](CC(C)C)C(=O)N[C@H](CCCCN)C(=O)N[C@H](CCC(O)=O)C(=O)N[C@H](CCCCN)C(=O)N[C@H](CCCCN)C(=O)N[C@H](CCC(O)=O)C(=O)N[C@H](C(C)C)C(=O)N[C@H](C(C)C)C(=O)N[C@H](CCC(O)=O)C(=O)N[C@H](CCC(O)=O)C(=O)N[C@@H](C)C(=O)N[C@H](CCC(O)=O)C(O)=O LCJVIYPJPCBWKS-NXPQJCNCSA-N 0.000 description 2
- 230000005951 type IV hypersensitivity Effects 0.000 description 2
- 208000027930 type IV hypersensitivity disease Diseases 0.000 description 2
- BDHUTRNYBGWPBL-HNNXBMFYSA-N (2s)-2-[(2-methylpropan-2-yl)oxycarbonylamino]-6-(phenylmethoxycarbonylamino)hexanoic acid Chemical compound CC(C)(C)OC(=O)N[C@H](C(O)=O)CCCCNC(=O)OCC1=CC=CC=C1 BDHUTRNYBGWPBL-HNNXBMFYSA-N 0.000 description 1
- ADFXKUOMJKEIND-UHFFFAOYSA-N 1,3-dicyclohexylurea Chemical compound C1CCCCC1NC(=O)NC1CCCCC1 ADFXKUOMJKEIND-UHFFFAOYSA-N 0.000 description 1
- ASOKPJOREAFHNY-UHFFFAOYSA-N 1-Hydroxybenzotriazole Chemical compound C1=CC=C2N(O)N=NC2=C1 ASOKPJOREAFHNY-UHFFFAOYSA-N 0.000 description 1
- YEDUAINPPJYDJZ-UHFFFAOYSA-N 2-hydroxybenzothiazole Chemical compound C1=CC=C2SC(O)=NC2=C1 YEDUAINPPJYDJZ-UHFFFAOYSA-N 0.000 description 1
- QCQCHGYLTSGIGX-GHXANHINSA-N 4-[[(3ar,5ar,5br,7ar,9s,11ar,11br,13as)-5a,5b,8,8,11a-pentamethyl-3a-[(5-methylpyridine-3-carbonyl)amino]-2-oxo-1-propan-2-yl-4,5,6,7,7a,9,10,11,11b,12,13,13a-dodecahydro-3h-cyclopenta[a]chrysen-9-yl]oxy]-2,2-dimethyl-4-oxobutanoic acid Chemical compound N([C@@]12CC[C@@]3(C)[C@]4(C)CC[C@H]5C(C)(C)[C@@H](OC(=O)CC(C)(C)C(O)=O)CC[C@]5(C)[C@H]4CC[C@@H]3C1=C(C(C2)=O)C(C)C)C(=O)C1=CN=CC(C)=C1 QCQCHGYLTSGIGX-GHXANHINSA-N 0.000 description 1
- QTBSBXVTEAMEQO-UHFFFAOYSA-M Acetate Chemical compound CC([O-])=O QTBSBXVTEAMEQO-UHFFFAOYSA-M 0.000 description 1
- 239000005695 Ammonium acetate Substances 0.000 description 1
- CPELXLSAUQHCOX-UHFFFAOYSA-M Bromide Chemical compound [Br-] CPELXLSAUQHCOX-UHFFFAOYSA-M 0.000 description 1
- ZAMOUSCENKQFHK-UHFFFAOYSA-N Chlorine atom Chemical compound [Cl] ZAMOUSCENKQFHK-UHFFFAOYSA-N 0.000 description 1
- KRKNYBCHXYNGOX-UHFFFAOYSA-K Citrate Chemical compound [O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O KRKNYBCHXYNGOX-UHFFFAOYSA-K 0.000 description 1
- 108010016626 Dipeptides Proteins 0.000 description 1
- GHASVSINZRGABV-UHFFFAOYSA-N Fluorouracil Chemical compound FC1=CNC(=O)NC1=O GHASVSINZRGABV-UHFFFAOYSA-N 0.000 description 1
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 1
- 241000124008 Mammalia Species 0.000 description 1
- 241001465754 Metazoa Species 0.000 description 1
- 241000699670 Mus sp. Species 0.000 description 1
- 229910019142 PO4 Inorganic materials 0.000 description 1
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 1
- QAOWNCQODCNURD-UHFFFAOYSA-L Sulfate Chemical compound [O-]S([O-])(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-L 0.000 description 1
- 210000001744 T-lymphocyte Anatomy 0.000 description 1
- KRNYOVHEKOBTEF-YUMQZZPRSA-N Val-Val Chemical compound CC(C)[C@H](N)C(=O)N[C@@H](C(C)C)C(O)=O KRNYOVHEKOBTEF-YUMQZZPRSA-N 0.000 description 1
- KZSNJWFQEVHDMF-UHFFFAOYSA-N Valine Natural products CC(C)C(N)C(O)=O KZSNJWFQEVHDMF-UHFFFAOYSA-N 0.000 description 1
- 230000002378 acidificating effect Effects 0.000 description 1
- 108010005233 alanylglutamic acid Proteins 0.000 description 1
- 229940024606 amino acid Drugs 0.000 description 1
- 235000001014 amino acid Nutrition 0.000 description 1
- 125000000539 amino acid group Chemical group 0.000 description 1
- 150000001413 amino acids Chemical class 0.000 description 1
- 229940043376 ammonium acetate Drugs 0.000 description 1
- 235000019257 ammonium acetate Nutrition 0.000 description 1
- 150000001450 anions Chemical class 0.000 description 1
- 239000007864 aqueous solution Substances 0.000 description 1
- 229940072107 ascorbate Drugs 0.000 description 1
- 235000010323 ascorbic acid Nutrition 0.000 description 1
- 239000011668 ascorbic acid Substances 0.000 description 1
- WPYMKLBDIGXBTP-UHFFFAOYSA-N benzoic acid Chemical compound OC(=O)C1=CC=CC=C1 WPYMKLBDIGXBTP-UHFFFAOYSA-N 0.000 description 1
- COSOUWSZFHWATE-VIFPVBQESA-N benzyl (2s)-2,4-diamino-4-oxobutanoate Chemical compound NC(=O)C[C@H](N)C(=O)OCC1=CC=CC=C1 COSOUWSZFHWATE-VIFPVBQESA-N 0.000 description 1
- 230000037396 body weight Effects 0.000 description 1
- 239000000872 buffer Substances 0.000 description 1
- TVFDJXOCXUVLDH-UHFFFAOYSA-N caesium atom Chemical class [Cs] TVFDJXOCXUVLDH-UHFFFAOYSA-N 0.000 description 1
- 150000001768 cations Chemical class 0.000 description 1
- 239000000460 chlorine Substances 0.000 description 1
- 229910052801 chlorine Inorganic materials 0.000 description 1
- 239000012230 colorless oil Substances 0.000 description 1
- 239000002178 crystalline material Substances 0.000 description 1
- 230000004069 differentiation Effects 0.000 description 1
- VDQVEACBQKUUSU-UHFFFAOYSA-M disodium;sulfanide Chemical compound [Na+].[Na+].[SH-] VDQVEACBQKUUSU-UHFFFAOYSA-M 0.000 description 1
- 239000002552 dosage form Substances 0.000 description 1
- 238000002474 experimental method Methods 0.000 description 1
- 239000004744 fabric Substances 0.000 description 1
- 229960002949 fluorouracil Drugs 0.000 description 1
- 239000012213 gelatinous substance Substances 0.000 description 1
- 238000002523 gelfiltration Methods 0.000 description 1
- 229910000040 hydrogen fluoride Inorganic materials 0.000 description 1
- NPZTUJOABDZTLV-UHFFFAOYSA-N hydroxybenzotriazole Substances O=C1C=CC=C2NNN=C12 NPZTUJOABDZTLV-UHFFFAOYSA-N 0.000 description 1
- 239000012535 impurity Substances 0.000 description 1
- 238000002347 injection Methods 0.000 description 1
- 239000007924 injection Substances 0.000 description 1
- 238000001990 intravenous administration Methods 0.000 description 1
- 238000004255 ion exchange chromatography Methods 0.000 description 1
- 229940049920 malate Drugs 0.000 description 1
- VZCYOOQTPOCHFL-UPHRSURJSA-N maleic acid Chemical compound OC(=O)\C=C/C(O)=O VZCYOOQTPOCHFL-UPHRSURJSA-N 0.000 description 1
- BJEPYKJPYRNKOW-UHFFFAOYSA-N malic acid Chemical compound OC(=O)C(O)CC(O)=O BJEPYKJPYRNKOW-UHFFFAOYSA-N 0.000 description 1
- 230000001404 mediated effect Effects 0.000 description 1
- 230000008018 melting Effects 0.000 description 1
- 238000002844 melting Methods 0.000 description 1
- BQERJWRZLXZNIO-RSAXXLAASA-N n-cyclohexylcyclohexanamine;(2s)-2-[(2-methylpropan-2-yl)oxycarbonylamino]-6-(phenylmethoxycarbonylamino)hexanoic acid Chemical compound C1CCCCC1NC1CCCCC1.CC(C)(C)OC(=O)N[C@H](C(O)=O)CCCCNC(=O)OCC1=CC=CC=C1 BQERJWRZLXZNIO-RSAXXLAASA-N 0.000 description 1
- 150000007530 organic bases Chemical class 0.000 description 1
- 239000012074 organic phase Substances 0.000 description 1
- 239000008188 pellet Substances 0.000 description 1
- NBIIXXVUZAFLBC-UHFFFAOYSA-K phosphate Chemical compound [O-]P([O-])([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-K 0.000 description 1
- 239000010452 phosphate Substances 0.000 description 1
- 229920001184 polypeptide Polymers 0.000 description 1
- 229920005990 polystyrene resin Polymers 0.000 description 1
- 159000000001 potassium salts Chemical class 0.000 description 1
- 230000001681 protective effect Effects 0.000 description 1
- 238000000746 purification Methods 0.000 description 1
- 239000002002 slurry Substances 0.000 description 1
- 229910052708 sodium Inorganic materials 0.000 description 1
- 239000011780 sodium chloride Substances 0.000 description 1
- 229910052979 sodium sulfide Inorganic materials 0.000 description 1
- 239000008223 sterile water Substances 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- KDYFGRWQOYBRFD-UHFFFAOYSA-L succinate(2-) Chemical compound [O-]C(=O)CCC([O-])=O KDYFGRWQOYBRFD-UHFFFAOYSA-L 0.000 description 1
- 229910021653 sulphate ion Inorganic materials 0.000 description 1
- 108700016958 thymosin fraction 5 Proteins 0.000 description 1
- VZCYOOQTPOCHFL-UHFFFAOYSA-N trans-butenedioic acid Natural products OC(=O)C=CC(O)=O VZCYOOQTPOCHFL-UHFFFAOYSA-N 0.000 description 1
- 239000004474 valine Substances 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
- C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
- C07K5/06—Dipeptides
- C07K5/06086—Dipeptides with the first amino acid being basic
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/04—Immunostimulants
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/575—Hormones
- C07K14/57581—Thymosin; Related peptides
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
- C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
- C07K5/06—Dipeptides
- C07K5/06008—Dipeptides with the first amino acid being neutral
- C07K5/06017—Dipeptides with the first amino acid being neutral and aliphatic
- C07K5/06034—Dipeptides with the first amino acid being neutral and aliphatic the side chain containing 2 to 4 carbon atoms
- C07K5/06043—Leu-amino acid
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
- C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
- C07K5/10—Tetrapeptides
- C07K5/1002—Tetrapeptides with the first amino acid being neutral
- C07K5/1005—Tetrapeptides with the first amino acid being neutral and aliphatic
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02P—CLIMATE CHANGE MITIGATION TECHNOLOGIES IN THE PRODUCTION OR PROCESSING OF GOODS
- Y02P20/00—Technologies relating to chemical industry
- Y02P20/50—Improvements relating to the production of bulk chemicals
- Y02P20/55—Design of synthesis routes, e.g. reducing the use of auxiliary or protecting groups
Landscapes
- Chemical & Material Sciences (AREA)
- Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Biochemistry (AREA)
- Biophysics (AREA)
- Genetics & Genomics (AREA)
- Molecular Biology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Immunology (AREA)
- Toxicology (AREA)
- General Chemical & Material Sciences (AREA)
- Gastroenterology & Hepatology (AREA)
- Endocrinology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Zoology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Peptides Or Proteins (AREA)
Description
Thymosin er en varmestabil sterk sur polypeptid forbindelse med 28 aminosyre-rester med den følgende sekvens: Thymosin is a heat-stable strong acidic polypeptide compound with 28 amino acid residues with the following sequence:
Dette peptidet som er et sterkt immunopotensierende middel blir isolert fra thymosin-fraksjon 5 av Goldstein et al. ved en kombinasjon av ione-bytte kromatografi og gel-filtrering (Proe. Natl.Acad. Sei. USA _74_, 725-729 (1977)). This peptide which is a strong immunopotentiating agent is isolated from thymosin fraction 5 by Goldstein et al. by a combination of ion-exchange chromatography and gel filtration (Proe. Natl. Acad. Sei. USA _74_, 725-729 (1977)).
Det er nå funnet at bestemte peptider som er sekvensfrag-menter av tymosin også viser immunopotensiell aktivitet, dvs. de påvirker reguleringen, differensieringen og funk-sjonen til T-celler It has now been found that certain peptides which are sequence fragments of thymosin also show immunopotential activity, i.e. they influence the regulation, differentiation and function of T cells
Følgelig vedrører foreliggende oppfinnelse en analogifremgangsmåte ved fremstilling av peptider med den generelle formel hvori R<1> er hydrogen, H-Glu-Lys-Lys- eller og av farmasøytisk fordraqelige salter derav, hvilken frem-gangsmåte består i å fjerne beskyttelsesgruppene fra et beskyttet peptid med den generelle formel Accordingly, the present invention relates to an analogue method for the production of peptides with the general formula in which R<1> is hydrogen, H-Glu-Lys-Lys- or and of pharmaceutically acceptable salts thereof, which method consists in removing the protective groups from a protected peptide of the general formula
hvori R 2 er Boe, Boc-Glu(OBzl)-Lys(Z)-Lys(Z)- eller Bon er tert-butyloksykarbony1, wherein R 2 is Boe, Boc-Glu(OBzl)-Lys(Z)-Lys(Z)- or Bon is tert-butyloxycarbonyl,
Bzl er benzyl og Bzl is benzyl and
Z er benzyloksykarbonyl, Z is benzyloxycarbonyl,
og om ønsket, overføre den erholdte forbindelse i et farma-søytisk akseptabelt salt. and, if desired, converting the obtained compound into a pharmaceutically acceptable salt.
Fjerning av beskyttelsesgruppene fra et beskyttelsespeptid av formel II er lett å utføre ved i og for seg kjente metoder såsom f.eks. ved behandling med vannfri syre såsom hydrogen-fluorid, fortrinnsvis i nærvær av anisol. Removal of the protective groups from a protective peptide of formula II is easily carried out by known methods such as e.g. by treatment with anhydrous acid such as hydrogen fluoride, preferably in the presence of anisole.
Systemet som ble anvendt i den kjemiske syntese av peptidene med formel I var som følger: H-Glu(OBzl)-0H ble først koblet med Boc-Ala-OSu hvilket gav det beskyttede dipeptid fragmentet Boc-Ala-Glu(OBzl)-0H som så ble kondensert med HC1.H-Asn-OBzl via DCC/HOSu prosedyren til Wunsch and Drees, Chem. Ber. 99,110 (1966). Hydrokloridsaltet til aspargin benzylester ble fremstilt fra Boc-Asn-OBzl som igjen ble syntetisert fra handelsvare Boc-Asn-OH og benzylbromider ved bruk av cesiumsaltet av amino-syren. Boc-beskyttelsesgruppen ble fjernet ved en 30 min. behandling med 4N HC1 i tørt THF. The system used in the chemical synthesis of the peptides of formula I was as follows: H-Glu(OBzl)-OH was first coupled with Boc-Ala-OSu giving the protected dipeptide fragment Boc-Ala-Glu(OBzl)-OH which was then condensed with HC1.H-Asn-OBzl via the DCC/HOSu procedure of Wunsch and Drees, Chem. Pray. 99,110 (1966). The hydrochloride salt of asparagine benzyl ester was prepared from Boc-Asn-OBzl which was in turn synthesized from commercial Boc-Asn-OH and benzyl bromides using the cesium salt of the amino acid. The Boc protecting group was removed by a 30 min. treatment with 4N HCl in dry THF.
Reaksjonen mellom H-Glu(OBzl)-OH og Boc-Glu(OBzl)-OSu ga Boc-Glu(OBzl)-Glu(OBzl)-OH som en fargeløs klar olje. Den ble så brukt i syntesen The reaction between H-Glu(OBzl)-OH and Boc-Glu(OBzl)-OSu gave Boc-Glu(OBzl)-Glu(OBzl)-OH as a colorless clear oil. It was then used in the synthesis
av det beskyttede pentapeptid Boc-Glu(OBzl)-Glu(OBzl)-Ala-Glu(OBzl)-Asn-OBzl i en DCC/HOSu -bevirket fragment kondensasjon ved bruk av HC1 " H-Ala-Glu(OBzl)-Asn-OBzl sen stammet fra Boc-Ala-Glu(OBzl)-Asn-OBzl etter 4N HC1/THF behandling. Det forannevnte beskyttede pentapeptid ble oppnådd of the protected pentapeptide Boc-Glu(OBzl)-Glu(OBzl)-Ala-Glu(OBzl)-Asn-OBzl in a DCC/HOSu -mediated fragment condensation using HC1 " H-Ala-Glu(OBzl)-Asn -OBzl sen derived from Boc-Ala-Glu(OBzl)-Asn-OBzl after 4N HC1/THF treatment, the aforementioned protected pentapeptide was obtained
i godt utbytte sem krystallinsk rent materiale. in good yield as crystalline pure material.
For fremstillingen av det beskyttede oktapeptidet Boc-Glu (OBzi ) -Val-Val-Glu (OBzl) -G].u (OBz L) -Ala-Glu (OBzl) -Asn-OBzl, ble det nødvendige beskyttede tripeptidet Boc-Glu(OBzl)-Val-Val-OH først fremstilt. Boc-Val-OSu fikk reaqere med fritt valin hvilket gav Boc-Val-Val-OH som etter avblok-kering med 4N.HC1 i THF fulgt av omsetning med Boc-Glu(OBzl)-OSu ga det ønskede tripeptid som ble krystallisert som cyckloheksylarain salt Boc-Glu(OBzl)-Val-Val-OH ' CHA. Cykloheksyiaminsaltet ble overført i den fri syre og ble For the preparation of the protected octapeptide Boc-Glu (OBzi )-Val-Val-Glu (OBzl)-G].u (OBz L)-Ala-Glu (OBzl)-Asn-OBzl, the required protected tripeptide Boc-Glu (OBzl)-Val-Val-OH first prepd. Boc-Val-OSu was allowed to react with free valine which gave Boc-Val-Val-OH which after deblocking with 4N.HCl in THF followed by reaction with Boc-Glu(OBzl)-OSu gave the desired tripeptide which was crystallized as cyclohexylarain salt Boc-Glu(OBzl)-Val-Val-OH ' CHA. The cyclohexyamine salt was transferred into the free acid and became
så koblet med DCC i nærvær av HOSu til HC1 " H-Glu-(OBzl)-Glu(OBzl)-Ala-Giu(OBzl)-Asn-OBzl som stammet fra Boc-Glu (OBzl)-Glu(OBzl)-Ala-Glu(OBzl)-Asn-OBzl ved behandling med HC1 i THF. Det beskyttede oktapeptidet Boc-Glu(OBzl)-Val-Val-Glu(OBzl)-Glu(OBzl)-Ala-Glu (OBzl) -Asn-OBzl erholdtes i renset form som et amorft fast stoff. Beskyttelsesgruppen ble fjernet hydrogenolytisk etterfulgt av behandling - med trifluoreddiksyre på vanlig måte som ga det frie oktapeptidet Glu-Val-Val-Glu-Glu-Ala-Glu-Asn. Dette produktet ble renset ved ione-bytte-kolonnekromatografi og ga et tynnsjikt-kromatografisk papirelektrofore- then coupled with DCC in the presence of HOSu to HC1 " H-Glu-(OBzl)-Glu(OBzl)-Ala-Giu(OBzl)-Asn-OBzl which originated from Boc-Glu (OBzl)-Glu(OBzl)-Ala -Glu(OBzl)-Asn-OBzl on treatment with HC1 in THF The protected octapeptide Boc-Glu(OBzl)-Val-Val-Glu(OBzl)-Glu(OBzl)-Ala-Glu (OBzl) -Asn-OBzl was obtained in purified form as an amorphous solid. The protecting group was removed hydrogenolytically followed by treatment - with trifluoroacetic acid in the usual manner to give the free octapeptide Glu-Val-Val-Glu-Glu-Ala-Glu-Asn. This product was purified by ion -exchange column chromatography and gave a thin-layer chromatographic paper electrophoresis-
tisk homogent materiale. tically homogeneous material.
For syntesen av det beskyttede undekapeptidet Boc-Glu(OBzl)-Lys(Z)-Lys(Z)-Glu(OBzl)-Val-Val-Glu(OBzl)-Glu(OBzl)-Ala-Glu (OBzl)-Asn-OBzl, ble det nødvendige tripeptid fragmentet syntetisert utfra Boc-Lys(Z)-OSu og H-Lys(Z)-OH. Dipep- For the synthesis of the protected undecapeptide Boc-Glu(OBzl)-Lys(Z)-Lys(Z)-Glu(OBzl)-Val-Val-Glu(OBzl)-Glu(OBzl)-Ala-Glu (OBzl)-Asn -OBzl, the required tripeptide fragment was synthesized from Boc-Lys(Z)-OSu and H-Lys(Z)-OH. Dipep-
tidet Boe- Lys (Z)-Lys(Z)-OH som således erholdtes ble behandlet med 4N HC1 i THF og det dannede salt HC1. H-Lys(Z)-Lys(Z)-OH fikk så reagere med Boc-Glu(OBzl)-OSu hvilket the time Boe-Lys(Z)-Lys(Z)-OH thus obtained was treated with 4N HC1 in THF and the formed salt HC1. H-Lys(Z)-Lys(Z)-OH was then allowed to react with Boc-Glu(OBzl)-OSu which
ga det ønskede tripeptid Boc-Glu(OBzl)-Lys(Z)-Lys(Z)-OH. Tripeptidet ble så aktivert med DCC og HOSu ifølge Weygand et al., Z. Naturforsch. 21b, 426 (1966), og løsningen av den aktive tripeptidester Boc-Glu(OBzl)-Lys(Z)-Lys(Z)-OSu fremstilt in situ kombinert med trifluoracetatsaltet H-Glu(OBzl)-Val-Val-Glu(OBzl)-Glu(OBzl)-Ala-Glu(OBzl)-Asn-OBzl som stammet fra det tilsvarende blokkerte octapeptidet ved en 30 min. behandling med TFA. Etter tilsetning av en liten mengde av en base ble det ønskede beskyttede undecapeptidet Boc-Glu(OBzl)-Lys(Z)-Lys(Z)-Glu(OBzl)-Val-Val-Glu(OBzl)-Glu(OBzl)-Ala-Glu(OBzl)-Asn-OBzl med vannfri flussyre ga det fri undecapeptidet Glu-Lys-Lys-Glu-Val-Val-Glu-Glu-Ala-Glu-Asn sem var homogent ved papix-elektroforese etter ione-bytte-kolonne-kromatogra.fi. gave the desired tripeptide Boc-Glu(OBzl)-Lys(Z)-Lys(Z)-OH. The tripeptide was then activated with DCC and HOSu according to Weygand et al., Z. Naturforsch. 21b, 426 (1966), and the solution of the active tripeptide ester Boc-Glu(OBzl)-Lys(Z)-Lys(Z)-OSu prepared in situ combined with the trifluoroacetate salt H-Glu(OBzl)-Val-Val-Glu( OBzl)-Glu(OBzl)-Ala-Glu(OBzl)-Asn-OBzl which originated from the corresponding blocked octapeptide at a 30 min. treatment with TFA. After addition of a small amount of a base, the desired protected undecapeptide Boc-Glu(OBzl)-Lys(Z)-Lys(Z)-Glu(OBzl)-Val-Val-Glu(OBzl)-Glu(OBzl)- Ala-Glu(OBzl)-Asn-OBzl with anhydrous hydrofluoric acid gave the free undecapeptide Glu-Lys-Lys-Glu-Val-Val-Glu-Glu-Ala-Glu-Asn which was homogeneous by papix electrophoresis after ion-exchange column-chromatography.fi.
Syntesen av det beskyttede tetradecapeptidet fulgte et lig-nende skjema. Boc-Leu-OSu ble koblet med H-Lys(Z)-OH hvilket gav Boc-Leu-Lys(Z)-OH. Etter fjerning av KK-Boc-gruppen med 4N HC1 i THF og omsetning med Boc-Asp (OBzl)-OSu erholdtes det beskyttede tripeptidet Boc-Asp(OBzl)-Leu-Lys(Z)-OH sem et krystallinsk rent fast The synthesis of the protected tetradecapeptide followed a similar scheme. Boc-Leu-OSu was coupled with H-Lys(Z)-OH giving Boc-Leu-Lys(Z)-OH. After removal of the KK-Boc group with 4N HC1 in THF and reaction with Boc-Asp (OBzl)-OSu, the protected tripeptide Boc-Asp(OBzl)-Leu-Lys(Z)-OH was obtained as a crystalline solid
stoff. Det ble overført i den aktive esteren Boc-Asp(OBzl)-Leu-Lys(Z)-OSu fabric. It was transferred in the active ester Boc-Asp(OBzl)-Leu-Lys(Z)-OSu
og kondensert med trifluoracetatsaltet av H-Glu(OBzl)-Lys(Z)-Lys(Z)-Glu (OBzl)-Val-Val-Glu(OBzl)-Glu(OBzl)-Ala-Glu(OBzl)-Asn-OBzl som erholdtes fra TFA-behandling av det tilsvarende blokkerte undecapeptidet. Det ønskede produktet Boc-Asp(OBzl)-Leu-Lys(Z)-Glu(OBzl)-Lys(Z)-Lys(Z)-Glu (OBzl)-Val-Val-Glu(OBzl)-Glu(OBzl)-Ala-Glu(OBzl)-Asn-OBzl erholdtes i and condensed with the trifluoroacetate salt of H-Glu(OBzl)-Lys(Z)-Lys(Z)-Glu (OBzl)-Val-Val-Glu(OBzl)-Glu(OBzl)-Ala-Glu(OBzl)-Asn- OBzl obtained from TFA treatment of the corresponding blocked undecapeptide. The desired product Boc-Asp(OBzl)-Leu-Lys(Z)-Glu(OBzl)-Lys(Z)-Lys(Z)-Glu (OBzl)-Val-Val-Glu(OBzl)-Glu(OBzl) -Ala-Glu(OBzl)-Asn-OBzl was obtained in
godt utbytte. Tynnsjikt-kromatografi indikerte at produktet var homogent. good yield. Thin layer chromatography indicated that the product was homogeneous.
Det fri tetradecapeptid Asp-Leu-Lys-Glu-Lys-Lys-Glu-Val-Val-Glu-Glu-Ala-Glu-Asn erholdtes fra den beskyttede forbindelsen ved behandling med vannfri flussyre og rensning på ione-bytter-kolonne. The free tetradecapeptide Asp-Leu-Lys-Glu-Lys-Lys-Glu-Val-Val-Glu-Glu-Ala-Glu-Asn was obtained from the protected compound by treatment with anhydrous hydrofluoric acid and purification on an ion-exchange column.
De nye okta-, undeca- eller tetradecapeptider og deres farma-søytisk fordragelige salter kan gis til varmblodige patte- The new octa-, undeca- or tetradecapeptides and their pharmaceutically acceptable salts can be administered to warm-blooded mammals
dyr ved parenteral applikasjon enten intravenøst, subkutant eller intramuskulc<;rt. Disse forbindelsene er sterke immunopotensierende midler ved en daglig dosering i området fra ca. 1-100 mg/kg kroppsvekt pr. dag ved intravenøs administrering. animals by parenteral application either intravenously, subcutaneously or intramuscularly. These compounds are strong immunopotentiating agents at a daily dosage in the range from approx. 1-100 mg/kg body weight per day by intravenous administration.
Åpenbart vil den nødvendige dose variere med den spesielle til-standen som behandles, tilstandens grad og behandlingens varighet. En egnet doseringsform for farmasøytisk anvendelse er et 1 mg frysetørket peptid som skal rekonstitueres før bruk ved tilsetning av sterilt vann eller saltvann. Obviously, the required dose will vary with the particular condition being treated, the degree of the condition and the duration of the treatment. A suitable dosage form for pharmaceutical use is a 1 mg freeze-dried peptide which must be reconstituted before use by adding sterile water or saline.
Den følgende tabell viser resultatene av et eksperiment som demonstrerer aktiviteten til peptider I (kalt okta-, undeka- The following table shows the results of an experiment demonstrating the activity of peptides I (called octa-, undeca-
og tetradekapeptider) ved fremkalling av forsinket type hypersensitivitet (DTH) reaksjon som delvis var undertrykket ved injeksjonen av 5-fluor-uracil (5-Fu) hos mus. and tetradecapeptides) in eliciting a delayed-type hypersensitivity (DTH) reaction that was partially suppressed by the injection of 5-fluoro-uracil (5-Fu) in mice.
De farmasøytisk fordragelige salter av de forannevnte pep- The pharmaceutically acceptable salts of the aforementioned pep-
tider omfatter natrium og kaliumsaltene eller salter med en sterk organisk base såsom guandin. Dertil kan anionene til disse kationene slik som klor, bromid, sulfat, fosfat, maleat, acetat, citrat, benzoat, succinat, malat, ascorbat o.l., times include the sodium and potassium salts or salts with a strong organic base such as guandine. In addition, the anions of these cations such as chlorine, bromide, sulphate, phosphate, maleate, acetate, citrate, benzoate, succinate, malate, ascorbate etc.,
inngå i preparatene. included in the preparations.
Forkortelsene som brukes heri har følgende betydning: Boc=t-butyloksykarbonyl; Bzl=benzyl; DCC=dicycloheksylkarbodimid; DMF=dimetylformamid; THF=tetrahydrofuran; HOSu= N-hydroksysuccin-imid; Triton B=4 0% metanolløsning av trimetylbenzylammonium hydroksyd; NMM=N-metylmorfolin; CHA=cycloheksylamin; DCHA= dicycloheksylamin; Z=benzyloksykarbonyl; DMSO=dimetylsulfok- The abbreviations used herein have the following meanings: Boc=t-butyloxycarbonyl; Bzl=benzyl; DCC=dicyclohexylcarbodiimide; DMF=dimethylformamide; THF=tetrahydrofuran; HOSu= N-hydroxysuccinimide; Triton B=4 0% methanol solution of trimethylbenzylammonium hydroxide; NMM=N-methylmorpholine; CHA=cyclohexylamine; DCHA= dicyclohexylamine; Z=benzyloxycarbonyl; DMSO=dimethylsulfoc-
syd; TFA=trifluoreddiksyre; TLC=tynnsjiktskromatografi; ET^N= trietylamin; HOBT=l-hydroksybenzotriazol. south; TFA=trifluoroacetic acid; TLC=thin layer chromatography; ET^N= triethylamine; HOBT=1-hydroxybenzotriazole.
De følgende eksempler beskriver i detalj syntesen av okta-, undeka-og tetradekapeptidene med formel I. The following examples describe in detail the synthesis of the octa-, undeca- and tetradecapeptides of formula I.
Selvom spesifikke beskyttelsesgrupper anvendes i disse Although specific protective groups are used in these
eksempler, vil det være åpenbart for enhver fagmann å anvende ekvivalente beskyttelsesgrupper i sådanne synteser. examples, it will be obvious to one skilled in the art to employ equivalent protecting groups in such syntheses.
Eksempel 1 Example 1
A.a) Boc-Asn-OH (11,0 g, 47,5 mmol) ble oppløst i 200 ml MeOH A.a) Boc-Asn-OH (11.0 g, 47.5 mmol) was dissolved in 200 mL of MeOH
og 20 ml vann ble tilsatt. Løsningen ble titrert til pH 7,0 and 20 ml of water was added. The solution was titrated to pH 7.0
med en 20% vandig løsning av Cs2C03 (ca. 55 ml). Blandingen ble inndampet til tørrhet og resten ble fordampet 2 ganger fra DMF (120 ml hver gang, 45°C). Det erholdte faste hvite stoff ble så rørt med 8,9 g benzylbromid (52 mmol) i 120 ml DMF i 6 timer. Ved inndampning til tørrhet og behandling med with a 20% aqueous solution of Cs 2 CO 3 (ca. 55 ml). The mixture was evaporated to dryness and the residue was evaporated twice from DMF (120 mL each time, 45°C). The white solid obtained was then stirred with 8.9 g of benzyl bromide (52 mmol) in 120 ml of DMF for 6 hours. By evaporation to dryness and treatment with
et stort volum vann, ble produktet øyeblikkelig fast. Det ble oppsamlet ved filtrering, oppløst i etylacetat, vasket med vann, tørket over Na2S04, inndampet til en fast masse og krystallisert fra etylacetat med petroleter. Utbytte 13,8 g (90,3%) av Boc-Asn-OBzl; smp. 120-122°C; 00 ^5= -17,29° (c=l,DMF). a large volume of water, the product immediately solidified. It was collected by filtration, dissolved in ethyl acetate, washed with water, dried over Na 2 SO 4 , evaporated to a solid and crystallized from ethyl acetate with petroleum ether. Yield 13.8 g (90.3%) of Boc-Asn-OBzl; m.p. 120-122°C; 00 δ = -17.29° (c=1, DMF).
Boc-Asn-OBzl (13,7 g, 42,4 mmol) ble oppløst i 80 ml THF Boc-Asn-OBzl (13.7 g, 42.4 mmol) was dissolved in 80 mL of THF
og behandlet med 500 ml 4N HC1 i THF. Blandingen fikk stå and treated with 500 mL of 4N HCl in THF. The mixture was allowed to stand
45 min. hvorunder noe produkt begynte å utfelles. Ved behandling med 1000 ml eter ble et hvitt faststoff øyeblikkelig dannet. Produktet ble filtrert, vasketmed eter og tørket over NaOH-pellets i vakuum. Utbytte: 10,3 g (94%) av HC1 'H-Asn-OBzl; smp. 122-126°C ;W^5=+6, 8 2°. b) H-Glu(OBzl)-OH (7,0 g, 29,5 mmol)' ble finknust med en morter og så rørt med 8,88 g (32,3 mmol) av Boc-Ala-OSu i 48 timer i 250 ml DMF i nærvær av 6 ml NMM. Noe mer NMM ble tilsatt for å holde miljøet svakt basisk under reaksjonen. Løsningsmiddelet ble avdampet og resten fordelt mellom 300 ml etylacetat og 500 ml H20 som inneholdt 2 ml av 10% H2S04- Det organiske sjiktet ble så vasket 3 ganger med vann, tørket over Na2S04 og inndampet til tørrhet. Produktet ble tatt opp i et lite volum eter og behandlet med et stort volum petroleter. Et hvitt amorft faststoff ble erholdt som var homogent i TCL. Utbytte: 11,0 g (91,5%) av Boc-Ala-Glu(OBzl)-OH; smp. 84-88°C; £- 1 ^<5> 8,08° (c=l,DMF). 45 min. below which some product began to precipitate. On treatment with 1000 ml of ether, a white solid formed immediately. The product was filtered, washed with ether and dried over NaOH pellets in vacuo. Yield: 10.3 g (94%) of HCl'H-Asn-OBzl; m.p. 122-126°C; W^5=+6.8 2°. b) H-Glu(OBzl)-OH (7.0 g, 29.5 mmol)' was finely crushed with a mortar and then stirred with 8.88 g (32.3 mmol) of Boc-Ala-OSu for 48 h in 250 ml DMF in the presence of 6 ml NMM. Some more NMM was added to keep the environment slightly basic during the reaction. The solvent was evaporated and the residue partitioned between 300 ml ethyl acetate and 500 ml H 2 O containing 2 ml of 10% H 2 SO 4 - The organic layer was then washed 3 times with water, dried over Na 2 SO 4 and evaporated to dryness. The product was taken up in a small volume of ether and treated with a large volume of petroleum ether. A white amorphous solid was obtained which was homogeneous in TCL. Yield: 11.0 g (91.5%) of Boc-Ala-Glu(OBzl)-OH; m.p. 84-88°C; £- 1 ^<5> 8.08° (c=1,DMF).
Boc-Ala-Glu(OBzl)-OH (10,4 g, 25,4 mmol), HC1 . H-Asn-OBzl Boc-Ala-Glu(OBzl)-OH (10.4 g, 25.4 mmol), HCl . H-Asn-OBzl
(6,56 g, 25", 4 mmol) og HOSu (5,9 g, 50,8 mmol) ble oppløst i DMF (250 ml, 0°C). DCC (5,7 g, 27,6 mmol) ble tilsatt umiddelbart etterfulgt av Et3N (3,5 ml). Blandingen ble rørt ved 0°C i to (6.56 g, 25", 4 mmol) and HOSu (5.9 g, 50.8 mmol) were dissolved in DMF (250 mL, 0 °C). DCC (5.7 g, 27.6 mmol) was added immediately followed by Et 3 N (3.5 mL).The mixture was stirred at 0°C for two
7 7
timer og så ved 25°C i 40 timer, hvorunder noe mer Et^N ble tilsatt fra tid til annen for å holde miljøet svakt basisk. hours and then at 25°C for 40 hours, during which a little more Et^N was added from time to time to keep the environment slightly basic.
De uløselige dannede biproduktene ble frafiltrert og filtratet inndampet til tørrhet. Det resterende oljeaktige materiale størknet ved behandling med vann. Råproduktet ble tatt opp i CHCl^ og vasket med vann (3x), tørket over Na2SO^ og inndam- The insoluble by-products formed were filtered off and the filtrate evaporated to dryness. The remaining oily material solidified on treatment with water. The crude product was taken up in CHCl^ and washed with water (3x), dried over Na2SO^ and concentrated
pet til et mindre volum. Noe faststoff som ble dannet på dette trinnet, ble frafiltrert (sterkt forurenset med dicyklohek-sylurea) og filtratet behandlet med petroleter. Et krystallinsk produkt ble erholdt. Utbytte: 8,0 g (51,4%) av Boc-Ala-Glu (OBzl ) -Asn-OBzl ) ; smp. 102-105°C;G^3 ^5 = 12,5° (c=l.,DMF) . pet to a smaller volume. Some solid formed in this step was filtered off (heavily contaminated with dicyclohexylurea) and the filtrate treated with petroleum ether. A crystalline product was obtained. Yield: 8.0 g (51.4%) of Boc-Ala-Glu(OBzl )-Asn-OBzl ); m.p. 102-105°C; G^3 ^5 = 12.5° (c=1., DMF) .
c) H-Glu(OBzl)-OH (4,74 g, 20 mmol) ble knust i en morter og rørt med Boc-Glu(OBzl)-OSu (0,7 g, 20 mmol) i DMF i c) H-Glu(OBzl)-OH (4.74 g, 20 mmol) was crushed in a mortar and stirred with Boc-Glu(OBzl)-OSu (0.7 g, 20 mmol) in DMF in
36 timer i nærvær av 3,6 ml NMM. Den dannede løsningen ble inndampet til en sirup og behandlet med vann. Den oljeaktige utfelling ble tatt opp i etylacetat, vasket først med 5% HOAc og så vann (3x), tørket over Na2SO^ og inndampet til tørrhet, hvilket gav 14,03 g av en klar olje. Den fikk stå under petroleter. Den resterende oljeaktige Boc-Glu(OBzl)-Glu(OBzl)- 36 hours in the presence of 3.6 ml of NMM. The resulting solution was evaporated to a syrup and treated with water. The oily precipitate was taken up in ethyl acetate, washed first with 5% HOAc and then water (3x), dried over Na 2 SO 4 and evaporated to dryness, yielding 14.03 g of a clear oil. It was allowed to stand under petrol. The remaining oily Boc-Glu(OBzl)-Glu(OBzl)-
OH veide 10,2 g (90%). TLC indikerte at produktet var homogent.M^5 -7,59° (c=l,DMF). OH weighed 10.2 g (90%). TLC indicated that the product was homogeneous.M^5 -7.59° (c=1, DMF).
d) Boc-Ala-Glu(OBzl)-Asn-OBzl) (28,2 g; 46 mmol ble behandlet med 1,1 liter 4N HC1 i THF i 1 time Avdampning av løsnings-middel og syreoverskudd etterlot en olje som ble inndampet 2 ganger til med friskt THF. Restoljen gikk over til et fast- d) Boc-Ala-Glu(OBzl)-Asn-OBzl) (28.2 g; 46 mmol was treated with 1.1 L of 4N HCl in THF for 1 h Evaporation of solvent and excess acid left an oil which was evaporated 2 more times with fresh THF The residual oil passed to a solid
stoff ved behandling med et stort volum eter. Det faste HCl H-Ala-Glu(OBzl)-Asn-OBzl ble rørt med Boc-Glu(OBzl)-Glu(OBzl)-OH 825,6 g, 46 mmol), HOSu (10,6 g, 92 mmol) og DCC 810,9 g 53 mmol) i DMF (54 0 ml) ved 0° i en time og så ved 25° i 48 timer. substance when treated with a large volume of ether. The solid HCl H-Ala-Glu(OBzl)-Asn-OBzl was stirred with Boc-Glu(OBzl)-Glu(OBzl)-OH 825.6 g, 46 mmol), HOSu (10.6 g, 92 mmol) and DCC 810.9 g 53 mmol) in DMF (540 mL) at 0° for one hour and then at 25° for 48 hours.
Et^N ble tilsatt for å holde miljøet svakt basisk over hele tidsrommet (ca. 16 ml Et^N totalt). De uløselige biproduk- Et^N was added to keep the environment slightly basic throughout the period (approx. 16 ml of Et^N in total). The insoluble byproducts
tene som ble dannet, ble frafiltrert og filtratet inndampet til tørrhet. Råproduktet ble oppløst i CHCl^, vasket med vann (3x), tørket over en Na2SO^ og inndampet til tørrhet. Produktet ble fast ved behandling med petroleter. Omkrystallisa-sjon fra isopropanol ga 28,9 g (59,8%) av Boc-Glu(OBzl)-Glu (OBzl)-Ala-Glu(OBzD-Asn-OBzl; smp. 16 9-17 5°C ;M ^5 =-11,78° the solids that formed were filtered off and the filtrate evaporated to dryness. The crude product was dissolved in CHCl 4 , washed with water (3x), dried over Na 2 SO 4 and evaporated to dryness. The product solidified on treatment with petroleum ether. Recrystallization from isopropanol gave 28.9 g (59.8%) of Boc-Glu(OBzl)-Glu (OBzl)-Ala-Glu(OBzD-Asn-OBzl; m.p. 16 9-17 5°C; M ^5 =-11.78°
(c=l,DMF). (c=1, DMF).
Boc-Glu(OBzl)-Glu(OBzl)-Ala-Glu(OBzl)-Asn-OBzl (3,9 g, 3,48 mmol) ble behandlet med 15 ml 4N HC1 i THF i 30 min. Noe krystallinsk produkt startet og dannes. Eter (210 ml) ble tilsatt og det utfelte faste stoff oppsamlet og vasket med eter. Rå-materialet ble krystallisert fra MeOH og eter. Utbytte: 2,58 Boc-Glu(OBzl)-Glu(OBzl)-Ala-Glu(OBzl)-Asn-OBzl (3.9 g, 3.48 mmol) was treated with 15 mL of 4N HCl in THF for 30 min. Some crystalline product started and forms. Ether (210 mL) was added and the precipitated solid was collected and washed with ether. The crude material was crystallized from MeOH and ether. Dividend: 2.58
g (75,1%) av HC1'H-Glu(OBzl)-Glu(OBzl)-Ala-Glu(OBzl)-Asn-OBzl: smp. 148-151°C:pJ^<5> = -3,65° (c=l, DMF). g (75.1%) of HC1'H-Glu(OBzl)-Glu(OBzl)-Ala-Glu(OBzl)-Asn-OBzl: m.p. 148-151°C: pJ^<5> = -3.65° (c=1, DMF).
e) Boc-Val-OSu (12,6 g, 40 mmol) og H-Val-OH (4,68 g, 40 e) Boc-Val-OSu (12.6 g, 40 mmol) and H-Val-OH (4.68 g, 40
mmol) ble kondensert i DMF 8250 ml) i 96 timer i nærvær av mmol) was condensed in DMF 8250 ml) for 96 h in the presence of
2 ml Et^N. Mer Et^N ble tilsatt ved behov for å holde miljøet svakt basisk. Det resterende uløselige materialet ble frafiltrert og filtratet inndampet til tørrhet (45°C). Resten ble fordelt mellom eter og fortynnet ^SO^ (ca. 1%). og det organiske sjiktet vasket med vann (3x), tørket over Na2S04 og inndampet til en skummet glassaktig masse. Produktet ble krystallisert fra eter og petroleter. Utbytte: 12,2 g (96,4%) av Boc-Val-Val-OH; smp. 155-158°C^5 = +1,10° (c = 1, DMF). 2 ml Et^N. More Et^N was added as needed to keep the environment slightly basic. The remaining insoluble material was filtered off and the filtrate evaporated to dryness (45°C). The residue was partitioned between ether and dilute ^SO^ (approx. 1%). and the organic layer washed with water (3x), dried over Na 2 SO 4 and evaporated to a frothy glassy mass. The product was crystallized from ether and petroleum ether. Yield: 12.2 g (96.4%) of Boc-Val-Val-OH; m.p. 155-158°C^5 = +1.10° (c = 1, DMF).
Boc-Val-Val-OH (40,5 g, 128 mmol) ble behandlet med 1,8 1 av Boc-Val-Val-OH (40.5 g, 128 mmol) was treated with 1.8 L of
4N HC1 i THF i 6 0 min. Inndampning for å fjerne overskuddet av syre og løsningsmiddel etterfulgt av behandling med eter ga 34,5 g HC1<*>H-Val-Val-0H som et hvitt amorft pulver. Det ble behandlet med Boc-Glu (OBzl)-OSu (55,6 g, 128 mmol) i 1 liter DMF i 24 timer i nærvær av 54 ml Et^N. Reaksjonsblandingen ble filtrert for å fjerne noe uløselig materiale og filtratet inndampet til tørrhet. Den gjenværende oljeaktige rest ble opptatt i EtOAc (1,5 1) og vasket med 5% HOAc (2x) etterfulgt av vann (3x). 4N HCl in THF for 60 min. Evaporation to remove excess acid and solvent followed by treatment with ether gave 34.5 g of HC1<*>H-Val-Val-OH as a white amorphous powder. It was treated with Boc-Glu(OBzl)-OSu (55.6 g, 128 mmol) in 1 L of DMF for 24 h in the presence of 54 mL of Et₂N. The reaction mixture was filtered to remove any insoluble material and the filtrate was evaporated to dryness. The remaining oily residue was taken up in EtOAc (1.5 L) and washed with 5% HOAc (2x) followed by water (3x).
Det organsike sjiktet ble tørket (Na2SO^) og inndampet til tørrhet og ga en fargeløs klar olje som ikke krystalliserte. The organic layer was dried (Na 2 SO 4 ) and evaporated to dryness to give a colorless clear oil which did not crystallize.
Den ble så oppløst i 3,2 1 eter og behandlet med CHA (17 ml) inntil blandingens pH var 7,5. Det faste erholdte salt ble oppsamlet og omkrystallisert fra MeOH og eter. Utbytte: 58,9 g 72,7%) av Boc-Glu(OBzl)-Val-Val-OH'CHA; smp. 158 - 160°C; It was then dissolved in 3.2 L of ether and treated with CHA (17 mL) until the pH of the mixture was 7.5. The solid salt obtained was collected and recrystallized from MeOH and ether. Yield: 58.9 g 72.7%) of Boc-Glu(OBzl)-Val-Val-OH'CHA; m.p. 158 - 160°C;
^] 25 = 33,41<0> (c = lf MeOH) . ^] 25 = 33.41<0> (c = 1f MeOH) .
Boc-Glu(OBzl)-Val-Val-OH"CHA (1,69 g, 2,66 mmol) ble opp- Boc-Glu(OBzl)-Val-Val-OH"CHA (1.69 g, 2.66 mmol) was prepared
slemmet i vann (40 ml) og etylacetat (40 ml) i en skille- slurry in water (40 ml) and ethyl acetate (40 ml) in a separatory
trakt under tilsetning av 4 ml 1 M H2S04. Etter kraftig rør- funnel while adding 4 ml of 1 M H2S04. After heavy pipe-
ing oppløstes det faste stoff, og det organiske sjiktet ble vasket flere ganger med vann, tørket over Na^SO^ og inn- ing, the solid was dissolved, and the organic layer was washed several times with water, dried over Na^SO^ and in-
dampet til en olje(81,45 g). Det således erholdte fri tripeptidet ble så kondensert med 2,58 g HC1' H-Glu(OBzl)-Glu(OBzl)-Ala-Glu(OBzl)-Asn-OBzl (2,61 mmol) i 15 ml DMF i nærvær av evaporated to an oil (81.45 g). The free tripeptide thus obtained was then condensed with 2.58 g of HCl' H-Glu(OBzl)-Glu(OBzl)-Ala-Glu(OBzl)-Asn-OBzl (2.61 mmol) in 15 ml of DMF in the presence of
HOSu (0,612 g, 5,32 mmol), NMM (0,3 ml, 2,66 mmol) og DCC (0,63 g, 3,0 6 mmol) i løpet av en time ved 0°C og 6 0 timer ved 25 C. HOSu (0.612 g, 5.32 mmol), NMM (0.3 mL, 2.66 mmol) and DCC (0.63 g, 3.0 6 mmol) during one hour at 0°C and 60 h at 25 C.
Mer NMM ble tilsatt ved behov for å -holde miljøet svakt basisk. Et uløselig dannet bi-produkt ble frafiltrert og filtratet inndampet til tørrhet (45°C). Den gjenblivende oljeaktiv- More NMM was added when needed to -keep the environment slightly alkaline. An insoluble by-product formed was filtered off and the filtrate evaporated to dryness (45°C). The remaining oil asset
resten størknet ved behandling med vann. Det faste råproduk- the rest solidified by treatment with water. The solid raw product
tet ble oppløst i DMF (50 ml) og felt med MeOH (300 ml). tet was dissolved in DMF (50 mL) and quenched with MeOH (300 mL).
Utbytte: 2,25 g (58,7%) Boc-Glu(OBzl)-Val-Val-Glu(OBzl)-Glu (OBzl)-Ala-Glu(OBzl)-Asn-OBzl; smp. 277-280°C C^J^5 = -12,43° Yield: 2.25 g (58.7%) Boc-Glu(OBzl)-Val-Val-Glu(OBzl)-Glu (OBzl)-Ala-Glu(OBzl)-Asn-OBzl; m.p. 277-280°C C^J^5 = -12.43°
(c = 1, DMF). (c = 1, DMF).
Dette produktet (0,72 g, 0,49 mmol) ble hydrogenert over 15% Pd/BaSO^ (0,5 g) i 3 timer ved 3,4 atm. i en blanding av 4 0 This product (0.72 g, 0.49 mmol) was hydrogenated over 15% Pd/BaSO 4 (0.5 g) for 3 h at 3.4 atm. in a mixture of 4 0
ml DMF/30 ml MeOH/ 2 ml H20. Blandingen ble så filtrert og filtratet inndampet til tørrhet. Det ble deretter behandlet med 5 ml TFA i 3 0 min. og den erholdte rest etter avdampning av syren ble revet flere ganger med eter. Det dannede faste stoffet ble tatt opp i vann (20 ml) og lyofilisert og ga ml DMF/30 ml MeOH/2 ml H 2 O. The mixture was then filtered and the filtrate evaporated to dryness. It was then treated with 5 ml of TFA for 30 min. and the residue obtained after evaporation of the acid was triturated several times with ether. The solid formed was taken up in water (20 mL) and lyophilized to give
0,47 g rå-produkt. Forbindelsen ble satt på en 3 x 32 cm kolonne av et sterkt basisk polystyrenharpiks (Bio-Rad AG1-X 2) som var ekvilibrert med pH 8,1 ammoniumacetatbuffer (2% HOAc inn-stilt på pH 8,1 med NH^). Kolonnen ble eluert suksessivt med 0.47 g crude product. The compound was loaded onto a 3 x 32 cm column of a strongly basic polystyrene resin (Bio-Rad AG1-X 2) equilibrated with pH 8.1 ammonium acetate buffer (2% HOAc adjusted to pH 8.1 with NH 2 ). The column was eluted successively with
200 ml av 0,025 M pH 5,5 NH4OAc, 0,025 m HOAc, 0,05 M HOAc, 200 ml of 0.025 M pH 5.5 NH4OAc, 0.025 M HOAc, 0.05 M HOAc,
0,25 M HOAc , 0,5 M HOAc, 0,75 M HOAc, IM HOAc. Fraksjoner .på 0.25 M HOAc, 0.5 M HOAc, 0.75 M HOAc, 1M HOAc. Fractions .on
12 ml ble oppsamlet og eluatet fra hvert rør undersøkt ved 12 ml was collected and the eluate from each tube examined by
TLC. Fraksjonene som inneholdt det ønskede materialet (rørene 225-229) ble slått sammen og lyofilisert 2 ganger og ga 0,223 TLC. The fractions containing the desired material (tubes 225-229) were pooled and lyophilized twice to give 0.223
g (48,1%) av ren Glu-Val-Val-Glu-Glu-Ala-Glu-Asn som var homogent i TLC og papir elektroforese. g (48.1%) of pure Glu-Val-Val-Glu-Glu-Ala-Glu-Asn which was homogeneous in TLC and paper electrophoresis.
Eksempel 2 Example 2
Boc-Lys(Z)-OH (15 g, 39,5 mmol) ble rørt med HOSu (5,3 g, Boc-Lys(Z)-OH (15 g, 39.5 mmol) was stirred with HOSu (5.3 g,
50,5 mmol) og 8,66 g, 42 mmol) i THF (250 ml) i tre timer. 50.5 mmol) and 8.66 g, 42 mmol) in THF (250 mL) for three hours.
Et uløselig biprodukt ble frafiltrert og filtratet inn- An insoluble by-product was filtered off and the filtrate in-
dampet til tørrhet. Den gjenværende sirup (24,2 g) ble behandlet med isopropanol (150 ml) og petroleter (150 ml) og ga et oljeaktig produkt (21 g) som ikke krystalliserte. Den rå aktive esteren Boc-Lys(Z)-OSu ble således brukt for kondensasjon med H-Lys(Z)-OH (10,6 g, 38 mmol) i DMF (250 ml) steamed to dryness. The remaining syrup (24.2 g) was treated with isopropanol (150 ml) and petroleum ether (150 ml) to give an oily product (21 g) which did not crystallize. The crude active ester Boc-Lys(Z)-OSu was thus used for condensation with H-Lys(Z)-OH (10.6 g, 38 mmol) in DMF (250 mL)
i 72 timer i nærvær av 5,5 ml Et^N. Mer Et^N ble tilsatt leilighetsvis for å holde den rørte reaksjonsblandingen svakt basisk. for 72 hours in the presence of 5.5 ml Et^N. More Et^N was added occasionally to keep the stirred reaction mixture slightly basic.
En liten mengde uoppløst materiale ble så frafiltrert og filtratet inndampet til tørrhet (45°C). Den tilbakeblivende olje-resten ble behandlet med 1,5 ml 5% HOAc. Det utfelte produktet ble ekstrahert over i etylacetat og den organiske fasen vasket med vann, tørket over Na2S©4 og inndampet til en olje. A small amount of undissolved material was then filtered off and the filtrate evaporated to dryness (45°C). The remaining oil residue was treated with 1.5 ml of 5% HOAc. The precipitated product was extracted into ethyl acetate and the organic phase washed with water, dried over Na2S©4 and evaporated to an oil.
Den ble krystallisert fra etylacetat (300 ml) som inneholdt DCHA (10 ml) som et salt. Omkrystallisasjonen fra MeOH og It was crystallized from ethyl acetate (300 mL) containing DCHA (10 mL) as a salt. The recrystallization from MeOH and
eter ga 22,7 g (72,5%) av Boc-Lys(Z)-Lys(Z)-OH'DCHA; smp. 160-16 2°C;E<:]^5 -2,21° (c = l,M.eOH). ether gave 22.7 g (72.5%) of Boc-Lys(Z)-Lys(Z)-OH'DCHA; m.p. 160-16 2°C; E<:]^5 -2.21° (c = 1.M.eOH).
Boc-Lys(Z)-OH DCHA (10 g, 12,14 mmol) ble fordelt mellom Boc-Lys(Z)-OH DCHA (10 g, 12.14 mmol) was partitioned between
EtOAc (1 liter) og 0,1 N H2S04 (1 liter). Det organiske sjiktet ble så vasket med vann (3x), tørket over Na2S04 og inndampet til tørrhet (7,9 g). Den fri syre, Boc-Lys(Z)-Lys(Z)-OH som således erholdtes, ble behandlet med friskt fremstilt 4N HC1 EtOAc (1 L) and 0.1 N H 2 SO 4 (1 L). The organic layer was then washed with water (3x), dried over Na 2 SO 4 and evaporated to dryness (7.9 g). The free acid, Boc-Lys(Z)-Lys(Z)-OH thus obtained, was treated with freshly prepared 4N HCl
i THF i 3 0 minutter. Løsningsmiddel og syre-overskudd ble avdampet (3 0°C) og resten inndampet igjen 2 ganger med THF. in THF for 30 minutes. Solvent and excess acid were evaporated (30°C) and the residue evaporated again 2 times with THF.
Den tilbakeblivende rest størknet ved behandling med eter. HC1<*>H.Lys(Z)-Lys(Z)-OH ble oppsamlet ved filtrering og vasket flere ganger med eter og ga 6,7 g hvitt pulver. Det ble oppløst i DMF (70 ml), kjølet i is-bad og behandlet med Et-^N (1,63 ml) fulgt av Boe- Glu(OBzl)-OSu (5,54 g, 12,76 mmol). Blandingen ble rørt i 0OC i en time og så ved 25°C i 24 timer. Mer Et-^N ,ble tilsatt i løpet av denne tiden for å holde reaksjonen nær pH 7,5. Noen ml eddiksyre ble tilsatt for å sur-gjøre miljøet (pH 3,5) og løsningsmiddelet fjernet ved inndampning. Den dannede resten ble tatt opp i EtOAc, vasket med vann (3x), tørket over Na2S04 og inndampet til tørrhet, hvorved produktet begynte å bli fast. Det ble revet i eter og omkrystallisert fra etylacetat. Utbytte: 7,26 g (69,5%) av Boc-Glu(OBzl)-Lys(Z)-Lys(Z)-OH; smp. 153-155°C; G-O^5 = -2,71° (c = 1, THF). The remaining residue solidified by treatment with ether. HC1<*>H.Lys(Z)-Lys(Z)-OH was collected by filtration and washed several times with ether to give 6.7 g of white powder. It was dissolved in DMF (70 mL), cooled in an ice bath and treated with Et-3N (1.63 mL) followed by Boe-Glu(OBzl)-OSu (5.54 g, 12.76 mmol). The mixture was stirred at 0°C for one hour and then at 25°C for 24 hours. More Et-3N was added during this time to keep the reaction close to pH 7.5. A few ml of acetic acid were added to acidify the environment (pH 3.5) and the solvent removed by evaporation. The resulting residue was taken up in EtOAc, washed with water (3x), dried over Na 2 SO 4 and evaporated to dryness, whereupon the product began to solidify. It was triturated in ether and recrystallized from ethyl acetate. Yield: 7.26 g (69.5%) of Boc-Glu(OBzl)-Lys(Z)-Lys(Z)-OH; m.p. 153-155°C; G-O^5 = -2.71° (c = 1, THF).
g) Boc-Glu(OBzl)-Val-Val-Glu(OBzl)-Glu(OBzl)-Ala-Glu(OBzl)-Asn-OBzl (1,7 g, 1,16 mmol ble behandlet med TFA (24 ml) i 30 g) Boc-Glu(OBzl)-Val-Val-Glu(OBzl)-Glu(OBzl)-Ala-Glu(OBzl)-Asn-OBzl (1.7 g, 1.16 mmol was treated with TFA (24 ml ) in 30
minutter. Etter fordampning av syre-overskudd (30°C) ble resten revet med eter. Det erholdte pulveret ble vasket grundig med eter og petroleter og tørket over NaOH i vakuum og ga trifluoracetatsaltet av oktapeptidet (1,71 g). Den aktive ester Boc-Glu(OBzl)-Lys(Z)-Lys(Z)-OSu ble så fremstilt in situ ved minutes. After evaporation of excess acid (30°C), the residue was triturated with ether. The powder obtained was washed thoroughly with ether and petroleum ether and dried over NaOH in vacuo to give the trifluoroacetate salt of the octapeptide (1.71 g). The active ester Boc-Glu(OBzl)-Lys(Z)-Lys(Z)-OSu was then prepared in situ by
å røre Boc-Glu(OBzl)-Lys(Z)-Lys(Z)-OH (0,998 g, 1,16 mmol), HOSu (0,16 g, 1,4 mmol) og DCC (0,274 g, 1,33 mmol) i 15 ml to stirring Boc-Glu(OBzl)-Lys(Z)-Lys(Z)-OH (0.998 g, 1.16 mmol), HOSu (0.16 g, 1.4 mmol) and DCC (0.274 g, 1, 33 mmol) in 15 ml
DMF i 0°C i 3 timer. Denne løsningen som inneholdt den aktive tripeptid-ester ble tilsatt oktapeptid-saltet CF3COOH'H-Glu (OBzl)-Val-Val-Glu(OBzl)-Glu(OBzl)-Ala-Glu(OBzl)-Asn-OBzl DMF at 0°C for 3 hours. To this solution containing the active tripeptide ester was added the octapeptide salt CF3COOH'H-Glu (OBzl)-Val-Val-Glu(OBzl)-Glu(OBzl)-Ala-Glu(OBzl)-Asn-OBzl
(1,71 g) sammen med 0,2 ml Et-^N. Noen flere dråper Et^N og DMF (15 ml) ble tilsatt og blandingen rørt 3 dager ved 25°C. En gelaktig halvfast-masse oppstod. Den ble surgjort ved eddiksyre og behandlet med vann. Det hvite faste presipitat ble oppsamlet og vasket (H20, MeOH, eter) og ga 2,2 5 g råprodukt som ble smeltet ved 310-313°C. Det ble oppløst i DMF og felt med MeOH. Utbytte: 1,75 g (68,3%) av Boc-Glu(OBzl)-Lys(Z)-Lys(Z)-Glu (OBzl)-Val-Val-Glu(OBzl)-Glu(OBzl)-Ala-Glu(OBzl)-Asn-OBzl; (1.71 g) along with 0.2 ml of Et-^N. A few more drops of Et₂N and DMF (15 mL) were added and the mixture was stirred for 3 days at 25°C. A gel-like semi-solid mass was formed. It was acidified with acetic acid and treated with water. The white solid precipitate was collected and washed (H 2 O, MeOH, ether) to give 2.25 g of crude product which melted at 310-313°C. It was dissolved in DMF and precipitated with MeOH. Yield: 1.75 g (68.3%) of Boc-Glu(OBzl)-Lys(Z)-Lys(Z)-Glu (OBzl)-Val-Val-Glu(OBzl)-Glu(OBzl)-Ala -Glu(OBzl)-Asn-OBzl;
smp. 314-316°C;l?<<i>3^<5> = 13,68° (c = 1, DMSO) ; homogent i TLC. m.p. 314-316°C; 1?<<i>3^<5> = 13.68° (c = 1, DMSO); homogeneous in TLC.
Boc-Glu(OBzl)-Lys(Z)-Lys(Z)-Glu(OBzl)-Val-Val-Glu(OBzl)-Glu (OBzl)-Ala-Glu(OBzl)-Asn-OBzl (0,5 g, 0,226 mmol) ble oppløst Boc-Glu(OBzl)-Lys(Z)-Lys(Z)-Glu(OBzl)-Val-Val-Glu(OBzl)-Glu (OBzl)-Ala-Glu(OBzl)-Asn-OBzl (0.5 g, 0.226 mmol) was dissolved
i 2 ml TFA og rørt med 15 ml HF ved 0°C i 15 min. Etter avdampning av syre-overskudd (0°C), ble resten oppløst i 5% . vandig HOAc, vasket med eter (3x), inndampet til et lite volum og lyofilisert og ga 0,34 g rått produkt. Det ble kromatografert på ionebytterkolonnen som er beskrevet ovenfor for oktapeptid og ga 0,13 g (42,1%) av ren^Glu-Lys-Lys-Glu-Val-Val-Glu-Glu-Ala-Glu-Asn;f<*] ^5 = -86, 65° (c = 1, H20) . in 2 ml TFA and stirred with 15 ml HF at 0°C for 15 min. After evaporation of excess acid (0°C), the residue was dissolved in 5% . aqueous HOAc, washed with ether (3x), evaporated to a small volume and lyophilized to give 0.34 g of crude product. It was chromatographed on the ion exchange column described above for octapeptide and gave 0.13 g (42.1%) of pure^Glu-Lys-Lys-Glu-Val-Val-Glu-Glu-Ala-Glu-Asn;f< *] ^5 = -86.65° (c = 1, H 2 O) .
Eksempel 3 Example 3
Boc-Leu-OSu (4,0 g, 12,2 mmol) og H-Lys(Z)-OH (3,42 g, 12,2 mmol) ble kondensert i DMF (75 ml) i løpet av 48 timer i nærvær av Et3N (1,7 ml). Reaksjonsblandingens pH ble holdt ved 7,5 ved tilsetning av Et^N periodisk som vanlig. Det gjenværende uløselige materialet ble utfelt og filtrert og filtratet inndampet til tørrhet. Den dannede skummete glassaktige massen ble oppløst i eter (200 ml) og blandingen behandlet med 3 ml DCHA for å gi krystallinsk materiale som ble oppsamlet, vasket med eter og omkrystallisert fra MeOH og eter. Utbytte: 5,7 g (69,5%) av Boc-Leu-Lys(Z)-OH.DCHA; smp. 140-142°C; <f6>! Q <5> = -7,20° (c = 1,MeOH) .Boc-Leu-Lys(Z)-OH.DCHA (2,97 g, Boc-Leu-OSu (4.0 g, 12.2 mmol) and H-Lys(Z)-OH (3.42 g, 12.2 mmol) were condensed in DMF (75 mL) over 48 h in presence of Et 3 N (1.7 mL). The pH of the reaction mixture was maintained at 7.5 by adding Et^N periodically as usual. The remaining insoluble material was precipitated and filtered and the filtrate evaporated to dryness. The foamy glassy mass formed was dissolved in ether (200 mL) and the mixture treated with 3 mL of DCHA to give crystalline material which was collected, washed with ether and recrystallized from MeOH and ether. Yield: 5.7 g (69.5%) of Boc-Leu-Lys(Z)-OH.DCHA; m.p. 140-142°C; <f6>! Q <5> = -7.20° (c = 1.MeOH).Boc-Leu-Lys(Z)-OH.DCHA (2.97 g,
4,4 mmol) ble overført i den fri syre (fordelt mellom EtOAc og 0,1 N H2S04), og den erholdte fargeløse olje (2,2 g) ble behandlet med 4N HC1 i THF (4 0 ml) i 30 min. Syre-overskuddet og løsningsmiddelet ble fordampet (30°C) og resten behandlet med eter. Den gjenblivende oljen ble oppløst i eter og inndampet 2 ganger til med ny eter. Resten ble så rørt med Boc-Asp(OBzl)-OSu (1,85 g, 4,4.mmol) i nærvær av Et^N (1,85 ml) natten over. Reaksjonsblandingen ble så inndampet til tørrhet og ga en oljerest som ble tatt opp i etylacetat, vasket med vann (3x), tørket over Na2S04 og inndampet til tørrhet igjen. Det° således erholdte rå-produkt ble krystallisert fra etylacetat og petroleter og ga 1,52 g (49,6%) av ren Boc-Asp(OBzl)-Leu-Lys(Z)-OH; smp. 109-111°C;[KJ ^<5> -16,14° 4.4 mmol) was taken up in the free acid (partitioned between EtOAc and 0.1 N H 2 SO 4 ), and the resulting colorless oil (2.2 g) was treated with 4N HCl in THF (40 mL) for 30 min. The excess acid and solvent were evaporated (30°C) and the residue treated with ether. The remaining oil was dissolved in ether and evaporated 2 more times with new ether. The residue was then stirred with Boc-Asp(OBzl)-OSu (1.85 g, 4.4 mmol) in the presence of Et₂N (1.85 mL) overnight. The reaction mixture was then evaporated to dryness to give an oil residue which was taken up in ethyl acetate, washed with water (3x), dried over Na 2 SO 4 and evaporated to dryness again. The crude product thus obtained was crystallized from ethyl acetate and petroleum ether and gave 1.52 g (49.6%) of pure Boc-Asp(OBzl)-Leu-Lys(Z)-OH; m.p. 109-111°C; [KJ ^<5> -16.14°
(c = 1, DMF). (c = 1, DMF).
Boc-Glu (OBzl) -Lys ( Z ) -Lys (Z ) -Glu (OBz 1) -Val-Val-Glu (0 Bzl) - Glu(OBzl)-Ala-Glu(OBzl)-Asn-OBzl (1,2 g, 0,545 mmol) ble behandlet med 35 ml TFA i 30 min. Syreoverskuddet ble raskt fordampet og resten revet med eter flere ganger og ga 1,'2 g av undecapeptid TFA-saltet som et hvitt pulver. Det ble opp-løst i en blanding av DMF (5 ml) og DMSO (2 ml) og behandlet med Boc-Asp(OBzl)-Leu-Lys(Z)-OSu fremstilt in situ ved å Boc-Glu (OBzl) -Lys ( Z ) -Lys (Z ) -Glu (OBz 1) -Val-Val-Glu (0 Bzl) - Glu(OBzl)-Ala-Glu(OBzl)-Asn-OBzl (1 .2 g, 0.545 mmol) was treated with 35 ml of TFA for 30 min. The excess acid was quickly evaporated and the residue triturated with ether several times to give 1.2 g of the undecapeptide TFA salt as a white powder. It was dissolved in a mixture of DMF (5 ml) and DMSO (2 ml) and treated with Boc-Asp(OBzl)-Leu-Lys(Z)-OSu prepared in situ by
røre Boc-Asp(OBzl)-Leu-Lys(Z)-OH (0,381 g, 0,545 mmol) stir Boc-Asp(OBzl)-Leu-Lys(Z)-OH (0.381 g, 0.545 mmol)
med HOSu (0,126 g, 1,1 mmol) og DCC (0,124 g, 0,599 mmol) i 3 ml DMF ved 0°C i tre timer. Blandingen som inneholdt den aktive tripeptid-esteren og undekapeptid ble rørt ved 0°C i 2 timer og så ved 25°C i tre dager, hvorunder Et^N ble tilsatt fra tid til annen for å holde pH with HOSu (0.126 g, 1.1 mmol) and DCC (0.124 g, 0.599 mmol) in 3 mL DMF at 0°C for three hours. The mixture containing the active tripeptide ester and undecapeptide was stirred at 0°C for 2 hours and then at 25°C for three days, during which Et^N was added from time to time to maintain the pH
svakt basisk. En gelatinaktig substans ble dannet. Den ble revet med 5% HOAc, og det resulterende hvite faste stoff ble filtrert og vasket med vann, MeOH og eter og ga 1,28 g rått materiale som smeltet ved 325-326°C. Omfelling fra DMF/DMSO (10 ml/5 ml) og MeOH weakly basic. A gelatinous substance was formed. It was triturated with 5% HOAc and the resulting white solid was filtered and washed with water, MeOH and ether to give 1.28 g of crude material melting at 325-326°C. Reprecipitate from DMF/DMSO (10 mL/5 mL) and MeOH
(230 ml) ga 1,22 g (80,2%) av ren Boc-Asp (OBzl)-Leu-Lys(Z)-Glu(OBzl)-Lys(Z)-Lys(Z)-Glu(OBzl)-Val-Val-Glu(OBzl)-Glu(OBzl)-Ala-Glu(OBzl)-Asn-OBzl); smp. 326-327°C;[<;>Op<5> = "15,71° (c= (230 mL) gave 1.22 g (80.2%) of pure Boc-Asp(OBzl)-Leu-Lys(Z)-Glu(OBzl)-Lys(Z)-Lys(Z)-Glu(OBzl) -Val-Val-Glu(OBzl)-Glu(OBzl)-Ala-Glu(OBzl)-Asn-OBzl); m.p. 326-327°C; [<;>Op<5> = "15.71° (c=
1, DMF/DMSO). 1, DMF/DMSO).
Dette produktet (1,128 g, 0,404 mmol) ble blandet med 7 ml anisol og behandlet med 25 ml vannfritt HF ved 0°C i 15 min. Syreoverskuddet ble avdampet (0°C) og den gjenblivende rest fordelt mellom eter og vann i Vann-sjiktet ble vasket 2 ganger med eter, inndampet til halvparten av det opprinnelige volumet og lyofilisert, hvilket ga 0,69 g rått materiale. Det ble kromatografert på den ovenfor beskrevne måte for oktapeptidet. Materialet som ble eluert i rørene 101-120, ble oppsamlet og lyofilisert, hvilket ga 0,25 g produkt som ble vist å være litt litt blandet med mindre forurensninger. Det ble derfor rekro-matografert på samme kolonne, hvilket ga 0,155 g (22%) ren Asp-Leu-Lys-Glu-Lys-Lys-Glu-Val-Val-Glu-Glu-Ala-Glu-Asn. Papirelektroforese tydet på at det var homogent• Ijx^lp"' = "86,27° This product (1.128 g, 0.404 mmol) was mixed with 7 mL of anisole and treated with 25 mL of anhydrous HF at 0°C for 15 min. The excess acid was evaporated (0°C) and the remaining residue partitioned between ether and water in the Water layer was washed 2 times with ether, evaporated to half the original volume and lyophilized, yielding 0.69 g of crude material. It was chromatographed in the manner described above for the octapeptide. The material eluted in tubes 101-120 was collected and lyophilized, yielding 0.25 g of product which was shown to be slightly mixed with minor impurities. It was therefore rechromatographed on the same column, which gave 0.155 g (22%) of pure Asp-Leu-Lys-Glu-Lys-Lys-Glu-Val-Val-Glu-Glu-Ala-Glu-Asn. Paper electrophoresis indicated that it was homogeneous• Ijx^lp"' = "86.27°
(c = 1, 0,1 N HC1). (c = 1, 0.1N HCl).
Claims (1)
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US78989877A | 1977-04-22 | 1977-04-22 | |
US05/871,563 US4116951A (en) | 1977-04-22 | 1978-01-23 | [Asn2 ]-thymosin α1 and analogs thereof |
Publications (3)
Publication Number | Publication Date |
---|---|
NO821608L NO821608L (en) | 1978-10-24 |
NO148924B true NO148924B (en) | 1983-10-03 |
NO148924C NO148924C (en) | 1984-01-11 |
Family
ID=27120967
Family Applications (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
NO781404A NO781404L (en) | 1977-04-22 | 1978-04-21 | PROCEDURE FOR THE PREPARATION OF THYMOSIN ALFA-1 AND AN ANALOG COMPOSITION |
NO821608A NO148924C (en) | 1977-04-22 | 1982-05-13 | ANALOGY PROCEDURE FOR THE PREPARATION OF IMMUNPOTENCING Peptides. |
Family Applications Before (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
NO781404A NO781404L (en) | 1977-04-22 | 1978-04-21 | PROCEDURE FOR THE PREPARATION OF THYMOSIN ALFA-1 AND AN ANALOG COMPOSITION |
Country Status (18)
Country | Link |
---|---|
JP (1) | JPS53137914A (en) |
AT (1) | AT364470B (en) |
CA (1) | CA1113088A (en) |
CH (3) | CH641152A5 (en) |
DE (1) | DE2817082A1 (en) |
DK (1) | DK147918C (en) |
ES (1) | ES469016A1 (en) |
FI (1) | FI781241A (en) |
FR (2) | FR2401134A1 (en) |
GB (1) | GB1590668A (en) |
GR (1) | GR71886B (en) |
HU (1) | HU180783B (en) |
IT (1) | IT1113134B (en) |
LU (1) | LU79488A1 (en) |
NL (1) | NL7804364A (en) |
NO (2) | NO781404L (en) |
PT (1) | PT67937B (en) |
SE (1) | SE447262B (en) |
Families Citing this family (7)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4116951A (en) * | 1977-04-22 | 1978-09-26 | Hoffmann-La Roche Inc. | [Asn2 ]-thymosin α1 and analogs thereof |
DE2919592A1 (en) * | 1979-05-15 | 1981-01-15 | Max Planck Gesellschaft | METHOD FOR PRODUCING THYMOSINE ALPHA 1 AND DERIVATIVES THEREOF |
EP0033384B1 (en) * | 1980-01-18 | 1984-02-15 | Max-Planck-Gesellschaft zur Förderung der Wissenschaften e.V. | Medicaments containing fragments of thymosin-alpha-1 with immunostimulating activity, and thymosin-alpha-1 fragments |
US4339427A (en) * | 1980-04-14 | 1982-07-13 | Hoffmann-La Roche Inc. | Radioimmunoassay of thymosinα |
EP0056594B1 (en) * | 1981-01-14 | 1984-09-12 | Max-Planck-Gesellschaft zur Förderung der Wissenschaften e.V. | Thymosin-alpha-1 fragments and pharmaceutical compositions with immunoregulating action containing them |
CN1058500C (en) * | 1993-02-03 | 2000-11-15 | 施塞克龙药品公司 | Thymosin alpha-1 derivatives |
US6262230B1 (en) * | 1994-01-28 | 2001-07-17 | Sciclone Pharmaceuticals Inc. | Analogs of thymosin α1 |
-
1978
- 1978-04-17 CH CH408878A patent/CH641152A5/en not_active IP Right Cessation
- 1978-04-18 DK DK169478A patent/DK147918C/en not_active IP Right Cessation
- 1978-04-19 DE DE19782817082 patent/DE2817082A1/en not_active Ceased
- 1978-04-20 GR GR56036A patent/GR71886B/el unknown
- 1978-04-20 FR FR7811686A patent/FR2401134A1/en active Granted
- 1978-04-21 HU HU78HO2067A patent/HU180783B/en unknown
- 1978-04-21 NO NO781404A patent/NO781404L/en unknown
- 1978-04-21 GB GB1574/78A patent/GB1590668A/en not_active Expired
- 1978-04-21 IT IT22629/78A patent/IT1113134B/en active
- 1978-04-21 PT PT67937A patent/PT67937B/en unknown
- 1978-04-21 AT AT0286178A patent/AT364470B/en not_active IP Right Cessation
- 1978-04-21 SE SE7804612A patent/SE447262B/en not_active IP Right Cessation
- 1978-04-21 LU LU79488A patent/LU79488A1/en unknown
- 1978-04-21 FI FI781241A patent/FI781241A/en not_active Application Discontinuation
- 1978-04-21 ES ES469016A patent/ES469016A1/en not_active Expired
- 1978-04-21 CA CA301,643A patent/CA1113088A/en not_active Expired
- 1978-04-21 JP JP4673978A patent/JPS53137914A/en active Pending
- 1978-04-24 NL NL7804364A patent/NL7804364A/en not_active Application Discontinuation
- 1978-12-15 FR FR7835404A patent/FR2405926A1/en active Granted
-
1982
- 1982-05-13 NO NO821608A patent/NO148924C/en unknown
- 1982-11-05 CH CH645082A patent/CH641153A5/en not_active IP Right Cessation
- 1982-11-05 CH CH644982A patent/CH640218A5/en not_active IP Right Cessation
Also Published As
Publication number | Publication date |
---|---|
NO781404L (en) | 1978-10-24 |
FR2401134B1 (en) | 1983-09-30 |
NL7804364A (en) | 1978-10-24 |
CA1113088A (en) | 1981-11-24 |
JPS53137914A (en) | 1978-12-01 |
IT7822629A0 (en) | 1978-04-21 |
LU79488A1 (en) | 1979-05-25 |
PT67937B (en) | 1980-04-07 |
NO821608L (en) | 1978-10-24 |
DE2817082A1 (en) | 1978-11-02 |
ATA286178A (en) | 1981-03-15 |
IT1113134B (en) | 1986-01-20 |
GR71886B (en) | 1983-08-04 |
DK147918C (en) | 1985-08-19 |
PT67937A (en) | 1978-05-01 |
FI781241A (en) | 1978-10-23 |
CH641153A5 (en) | 1984-02-15 |
SE447262B (en) | 1986-11-03 |
GB1590668A (en) | 1981-06-03 |
CH640218A5 (en) | 1983-12-30 |
FR2405926B1 (en) | 1983-09-09 |
AT364470B (en) | 1981-10-27 |
NO148924C (en) | 1984-01-11 |
DK169478A (en) | 1978-10-23 |
DK147918B (en) | 1985-01-07 |
SE7804612L (en) | 1978-12-20 |
CH641152A5 (en) | 1984-02-15 |
HU180783B (en) | 1983-04-29 |
FR2405926A1 (en) | 1979-05-11 |
FR2401134A1 (en) | 1979-03-23 |
ES469016A1 (en) | 1980-01-01 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
US4116951A (en) | [Asn2 ]-thymosin α1 and analogs thereof | |
US4148788A (en) | Synthesis of thymosin α1 | |
PT93245B (en) | METHOD FOR PREPARING NEW GLYCINE DERIVATIVES AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM | |
US5686421A (en) | Hydantoin derivates | |
NO140854B (en) | ANALOGICAL PROCEDURE FOR THE PREPARATION OF THERAPEUTIC ACTIVE NONAPEPTIDE AMIDES | |
SE447389B (en) | NEW TRIPEPTIDES AFFECTING THE CENTRAL NERVOUS SYSTEM | |
CA1267996A (en) | Peptides which are active on the central nervous system and have an action on the cholinergic system | |
US3978035A (en) | 13-Norleucine-14-desamido motilin, a method for preparing it and an agent containing it | |
NO148924B (en) | ANALOGY PROCEDURE FOR THE PREPARATION OF IMMUNPOTENTPENSING PEPTIDES | |
US3917578A (en) | Process for producing somatostatin and intermediates | |
US4647553A (en) | Gonadoliberin derivatives and process for the preparation thereof | |
US3749703A (en) | Asn15-bovine thyrocalcitonin | |
US3873511A (en) | (1-{60 -Aminoisobutyric acid)-corticotropin peptides | |
US3801561A (en) | Derivatives of salmon thyrocalcitonin | |
DE69418353T2 (en) | Cyclic pentapeptides with beta-turn and gamma-turn | |
PATTARONI et al. | Cyclic hexapeptides related to somatostatin synthesis and biological testing | |
US3873510A (en) | Peptides of ACTH activity containing {60 -aminooxy carboxylic acid on the N-terminal moiety, and a process for the preparation thereof | |
US4238390A (en) | Synthesis and biological activity of [D-Thr2, Δ3 Pro5 ]-enkephalinamide | |
US4474765A (en) | Biologically active peptides | |
US3300468A (en) | Octadecapeptides and intermediates in the preparation thereof | |
US3738978A (en) | Process for the manufacture of peptides | |
KR840000054B1 (en) | Process for the preparation of thymosin | |
Wang et al. | [Asn 2]-thymosin α 1 and analogs thereof | |
US3812092A (en) | Intermediates in the preparation of secretin | |
CA1123428A (en) | PROCESS FOR THE PREPARATION OF THYMOSIN .alpha..SUB.1 AND AN ANALOGUE |